Table 4.

Univariate analysis of clinical variables by HIN-1/RASSF1A and RIL/CDH13panels, according to Fisher's exact test

	HIN-1/RASSF1A panel			RIL/CDH13 panel
	Number negative (percentage)	Number positive (percentage)	p value	Number negative (percentage)	Number positive (percentage)	p value
Tumor size			0.502			0.999
1	11 (20)	8 (24)		14 (22)	5 (19)
2	20 (36)	16 (47)		25 (39)	11 (42)
3	12 (21)	6 (18)		13 (20)	5 (19)
4	13 (23)	4 (12)		12 (19)	5 (19)
Tumor grade (BNG)			0.015			0.162
1 + 2	25 (45)	25 (74)		39 (61)	11 (44)
3	30 (55)	9 (26)		25 (39)	14 (56)
Tumor stage			0.16			0.745
1	8 (14)	7 (21)		12 (19)	3 (12)
2	20 (36)	17 (50)		25 (39)	12 (46)
3	28 (50)	10 (29)		27 (42)	11 (42)
Lymph-node metastasis			0.558			0.78
PN0	24 (43)	15 (44)		26 (41)	13 (50)
PN1	16 (29)	12 (35)		22 (34)	6 (23)
PN2	5 (9)	4 (12)		6 (9)	3 (12)
PN3	11 (20)	3 (9)		10 (16)	4 (15)
Lymphatic invasion			0.244			0.805
1	25 (52)	20 (67)		32 (59)	13 (54)
2	23 (48)	10 (33)		22 (41)	11 (46)
Vascular invasion			0.346			0.623
1	26 (54)	20 (67)		33 (61)	13 (54)
2	22 (46)	10 (33)		21 (39)	11 (46)
ER status			< 0.001			0.001
Positive	22 (42)	30 (88)		44 (72)	8 (31)
Negative	31 (58)	4 (12)		17 (28)	18 (69)
PR status			< 0.001			0.033
Positive	16 (30)	24 (71)		33 (54)	7 (27)
Negative	37 (70)	10 (29)		28 (46)	19 (73)
HR status			< 0.001			0.001
Positive	24 (45)	31 (91)		46 (75)	9 (35)
Negative	29 (55)	3 (9)		15 (25)	17 (65)
HER-2/neu status			0.041			0.999
Positive	7 (14)	0 (0)		5 (9)	2 (8)
Negative	43 (86)	30 (100)		50 (91)	23 (92)
Triple-negative			0.001			< 0.001
No	33 (59)	31 (91)		53 (83)	11 (42)
Yes	23 (41)	3 (9)		11 (17)	15 (58)

BNG, Black's nuclear grade; ER, estrogen receptor; HR, hormone receptor; PR, progesterone receptor.